Compound containing imatinib and plant polysaccharide

Abstract

The invention provides a compound containing imatinib or pharmaceutically acceptable salt of the imatinib and plant polysaccharide. The plant polysaccharide is selected from one of ganoderma lucidum polysaccharide, coriolus versicolor polysaccharide and cynanchum otophyllum polysaccharide. Animal tests show that the compound can generate a synergistic anti-tumor effect on liver cancer, gastric cancer, a lung carcinoma model, gallbladder carcinoma and / or kidney cancer.

Description

technical field

[0001] The invention relates to the technical field of medicine, in particular to a composition containing imatinib and plant polysaccharides. Background technique

[0002] Imatinib (also known as STI-571, CGP57148B) is a phenylaminopyrimidine derivative with a chemical name of (4-[(4-methyl-1-piperazine)methyl]-N-[ 4-Methyl-3-{(4-(3-pyridine)2-pyrimidine)}amino]phenyl)aniline, its mesylate salt for medicinal purposes, its structural formula is shown below.

[0003]

[0004] Imatinib is a selective tyrosine kinase inhibitor, which inhibits its tyrosine kinase activity by competitively binding to the ATP-binding site on BCR-ABL kinase, blocking the kinase's autophosphorylation and Substrate phosphorylation level, thereby specifically inhibiting the proliferation of BCR-ABL positive cells and inducing their apoptosis. The FDA-approved indications for imatinib include hematological tumors such as chronic myeloid leukemia (CML) and solid tumors such as gastr...

Images